High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline: A new marker of chronic angiotensin-converting enzyme inhibition

Hypertension

Volumn 30, Issue 5, 1997, Pages 1015-1019

  Azizi, Michel ^a,c   Ezan, Eric ^b   Nicolet, Laurence ^a   Grognet, Jean Marc ^b   Ménard, Joël ^a  

^a INSERM   (France)

^b Institut National de la Recherche Agronomique   (France)

^c HÔPITAL BROUSSAIS   (France)

Author keywords

Angiotensin converting enzyme inhibition; Diagnosis; Patient compliance; Peptides

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LYSYLPROLINE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CELL CYCLE S PHASE; ELECTROLYTE BALANCE; ENZYME ACTIVE SITE; ENZYME SUBSTRATE; FEMALE; HUMAN; HYDROLYSIS; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECEPTOR AFFINITY; STEM CELL;

EID: 0030698849     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.30.5.1015     Document Type: Article

References (36)

1. Erdös EG. Angiotensin I converting enzyme and the changes in our concepts through the years. Hypertension. 1990;16:363-370.
2. Skidgel RA, Erdös EG. The broad substrate specificity of human angiotensin I converting enzyme. Clin Exp Hypertens. 1987;A9:243-259.
3. Wei L, Alhenc-Gelas F, Corvol P, Clauser E. The two homologous domains of human angiotensin I-converting enzyme are both catalytically active. J Biol Chem. 1991;266:9002-9008.
4. Lenfant M, Wdzieczak-Bakala J, Guittet E, Prome JC, Sotty D, Frindel E. Inhibitor of hematopoietic pluripotent stem cell proliferation: purification and determination of its structure. Proc Natl Acad Sci U S A. 1989;86:779-782.
5. Bonnet D, Lemoine FM, Ponvert-Delucq S, Baillou C, Najman A, Guignon M. Direct and reversible inhibitory effect of the tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (Seraspenide) on the growth of human CD34+ subpopulations in response to growth factors. Blood. 1993;82:3307-3314.
6. Guigon M, Bonnet D. Inhibitory peptides in hematopoiesis. Exp Hematol. 1995;23:477-481.
7. Jaspard E, Wei L, Alhenc-Gelas F. Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II): studies with bradykinin and other natural peptides. J Biol Chem. 1993;268:9496-9503.
8. Rieger K-J, Saez-Servent N, Papet M-P, Wdzieczak-Bakala J, Morgat J-L, Thierry J, Voelter W, Lenfant M. Involvement of human plasma angiotensin I-converting enzyme in the degradation of the haemoregulatory peptide N-acetyl seryl aspartyl lysyl proline. Biochem J. 1993;296:1-6.
9. Rousseau A, Michaud A, Chauvet M-T, Lenfant M, Corvol P. The hemoregulatory peptide N-ACetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme. J Biol Chem. 1995;270:3656-3661.
10. Azizi M, Rousseau A, Ezan E, Guyene TT, Michelet S, Grognet J-M, Lenfant M, Corvol P, Ménard J. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J Clin Invest. 1996; 97:839-844.
11. Delacretaz E, Nussberger J, Püchler K, Wood AJ, Robison PR, Waeber B, Brunner HR. Value of different clinical and biochemical correlates to assess angiotensin converting enzyme inhibition. J Cardiovasc Pharmacol. 1994;24:479-485.
12. Ezan E, Carde P, Le Kerneau J, Ardouin T, Thomas F, Isnard F, Deschamps de Paillette E, Grognet JM. Pharmacokinetics in healthy volunteers and patients of NAc-SDKP (Seraspenide), a negative regulator of hematopoiesis. Drug Metab Dispos. 1994;22:843-848.
13. Cushman DW, Cheung MS. Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung. Biochem Pharmacol. 1971;20:1637-1648.
14. Imbs JL, Bakish D, Schmidt M, Schwartz J. Low temperature sustains inhibition of angiotensin converting enzyme activity in serum from patients taking captopril. N Engl J Med. 1981;305:229.
15. Ménard J, Guyene TT, Chatellier G, Kleinbloesem CH, Bernadet P. Renin release regulation during acute renin inhibition in normal volunteers. Hypertension. 1991;18:257-265.
16. Ménard J, Guyene TT, Corvol P, Pau B, Simon D, Roncucci R. Direct radioimmunoassay of active renin in human plasma. J Hypertens. 1985;3(suppl 3):275-278.
17. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
18. Bland JM, Altman DG. The use of transformation when comparing two means. BMJ. 1996;312:1153.
19. Wei L, Clauser E, Alhenc-Gelas F, Corvol P. The two homologous domains of human angiotensin I-converting enzyme interact differently with competitive inhibitors. J Biol Chem. 1992;267:13398-13405.
20. Fyhrquist F, Forslund T, Tikkanen I, Gronhagen-Riska C. Induction of angiotensin converting enzyme in rat lung with captopril (SQ 14225). Eur J Pharmacol. 1980;67:473-475.
21. Jackson B, Johnston CI. Angiotensin converting enzyme during acute and chronic enalapril therapy in essential hypertension. Clin Exp Pharmacol Physiol. 1984;11:355-360.
22. Mooser V, Nussberger J, Juillerat L, Burnier M, Waeber B, Bidiville J, Pauly N, Brunner HR. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol. 1990;15:276-282.
23. Rasmussen S, Damkjaer Nielsen M, Giese J. Captopril combined with thiazide lowers renin substrate concentration: implications for methodology in renin assays. Clin Sci (Colch). 1981;60:591-593.
24. Jaramillo H, Sambhi M, Bouhnik J, Corvol P, Ménard J. Liver angiotensinogen synthesis and release during captopril treatment in sodium-depleted rats. Endocrinology. 1987;120:1384-1390.
25. Juillerat L, Nussberger J, Ménard J, Mooser V, Christen Y, Waeber B, Graf P, Brunner HR. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension. 1990;16:564-572.
26. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86:1343-1346.
27. Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F. Evidence from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet. 1992;51:197-205.
28. Stephenson BJ, Rowe BH, Haynes B, Macharia WM, Leon G. Is this patient taking the treatment as prescribed? JAMA. 1993;269: 2779-2781.
29. Nussberger J, Brunner D, Keller I, Brunner HR. Measurement of converting enzyme activity by antibody-trapping of generated angiotensin II. Am J Hypertens. 1992;5:393-398.
30. van Brummelen P, Willemze R, Ran WD, Thompson J. Captopril-associated agranulocytosis. Lancet. 1980;1:150.
31. Cooper RA. Captopril-associated neutropenia: Who is at risk? Arch Intern Med. 1983;143:659-660.
32. Hirakata H, Onoyama K, Iseki K, Kumagai H, Fujimi S, Omae T. Worsening of anemia induced by long-term use of captopril in hemodialysis patients. Am J Nephrol. 1984;4:355-360.
33. Elijovisch F, Krakoff LR. Captopril associated granulocytopenia in hypertension after renal transplantation. Lancet. 1980;1:927.
34. Sizeland PCB, Bailey RR, Lynn KL, Robson RA. Anemia and angiotensin converting enzyme inhibition in renal transplant recipients. J Cardiovasc Pharmacol. 1990;16(suppl 7):S117-S119.
35. Vlahakos DV, Canzanello VJ, Madaio MP, Madias NE. Enalapril-associated anemia in renal transplant recipients treated for hypertension. Am J Kidney Dis. 1991;17:199-205.
36. Casato M, Pucillo LP, Leoni M, Di Lullo L, Gabrielli A, Sansonno D, Dammacco F, Danieli G, Bonomo L. Granulocytopenia after combined therapy with interferon and angiotensin-converting enzyme inhibitors: evidence for a synergistic hematologic toxicity. Am J Med. 1995;99:386-391.